Octagon Capital Advisors
$1.1B 13F equity value
33 Holdings
Quarter ended June 30, 2026
The latest 13F on file for Octagon Capital Advisors covers the quarter ended June 30, 2026. Institutional managers report holdings quarterly to the SEC, so each filing is a snapshot of positions held on that date.
Top Holdings
| Ticker | Company | Shares | Value | Weight |
|---|---|---|---|---|
| DNTH | DIANTHUS THERAPEUTICS INC | 1,841,667 | $180M | 16.5% |
| DFTX | DEFINIUM THERAPEUTICS INC | 2,950,000 | $139M | 12.7% |
| ABVX | ABIVAX SA | 993,000 | $132M | 12.1% |
| COGT | COGENT BIOSCIENCES INC | 2,350,000 | $91M | 8.3% |
| ALMS | ALUMIS INC | 2,830,700 | $80M | 7.3% |
| AVBP | ARRIVENT BIOPHARMA INC | 1,971,054 | $68M | 6.3% |
| TSHA | TAYSHA GENE THERAPIES INC | 9,693,244 | $66M | 6.1% |
| BIOA | BIOAGE LABS INC | 1,748,000 | $43M | 3.9% |
| MIRM | MIRUM PHARMACEUTICALS INC | 338,900 | $40M | 3.6% |
| KYMR | KYMERA THERAPEUTICS INC | 310,000 | $36M | 3.3% |
Track Octagon Capital Advisors's 13F portfolio: $1.1B in reported holdings, 33 positions. Top holdings and quarterly changes on SentiSense.
This page is powered by the SentiSense API: GET /api/v1/institutional/institution/{slugOrCik}